Table 2.
Performance of the 7-Gene Algorithm and clinicopathological factors for distinguishing progression and non-progression after treatment in the MSK cohort (n = 471) and the TCGA progression cohort (n = 191).
| Sensitivity (95% CI) |
Specificity (95% CI) |
PPV (95% CI) |
NPV (95% CI) |
|
|---|---|---|---|---|
| Prediction of Progression in the MSK Cohort (n = 471) | ||||
| 7-Gene Algorithm | 83% (68–98%) | 98% (97–100%) | 74% (58–91%) | 99% (98–100%) |
| Cancer stage | 0% (0–0%) | 100% (100–100%) | 0% (0–0%) | 95% (93–97%) |
| Adjuvant therapies | 0% (0–0%) | 100% (100–100%) | 0% (0–0%) | 95% (93–97%) |
| Surgery on primary tumor | 0% (0–0%) | 100% (100–100%) | 0% (0–0%) | 95% (93–97%) |
| MSI | 0% (0–0%) | 100% (100–100%) | 0% (0–0%) | 95% (93–97%) |
| Combination | 83% (68–98%) | 99% (97–100%) | 77% (61–93%) | 99% (98–100%) |
| Prediction of Progression in the TCGA Progression Cohort (n = 191) | ||||
| 7-Gene Algorithm | 96% (93–99%) | 77% (62–92%) | 96% (93–99%) | 79% (65–94%) |
| Cancer stage | 100% (100–100%) | 0% (0–0%) | 85% (79–89%) | 0% (0–0%) |
| Adjuvant therapies | 100% (100–100%) | 0% (0–0%) | 84% (79–89%) | 0% (0–0%) |
| Combination | 96% (93–99%) | 77% (62–92%) | 96% (93–99%) | 79% (65–94%) |
CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value; MSI: microsatellite instability.